New belly fat injection cuts dangerous fat surrounding organs by 12% in early human trial — Live Feedhttps://www.live-feeds.com/feed/new-belly-fat-injection-cuts-dangerous-fat-surrounding-organs-by-12-in-early-human-trialContinuously updated, source-cited coverage. Experimental belly fat injection reduces visceral fat by 12% in early human trialshttps://www.live-feeds.com/feed/new-belly-fat-injection-cuts-dangerous-fat-surrounding-organs-by-12-in-early-human-trialhttps://www.live-feeds.com/feed/new-belly-fat-injection-cuts-dangerous-fat-surrounding-organs-by-12-in-early-human-trial#u122598Thu, 15 Oct 2026 01:34:43 +0000An experimental injection, CBL-514, has shown promising results in reducing visceral fat in early human trials. The injection, developed by Caliway Biopharmaceuticals, triggers apoptosis in fat cells, leading to a significant reduction in dangerous belly fat surrounding organs. In a phase 2 MRI analysis, recipients had an average 12.01% reduction in visceral fat four weeks after treatment. This breakthrough could potentially open a new path to treating obesity and related health risks.Why it mattersThe reduction of visceral fat is crucial as it is linked to various health risks, including type